&lt;p&gt;The impact of panitumumab treatment on survival and quality of life in patients with &lt;em&gt;RAS&lt;/em&gt; wild-type metastatic colorectal cancer&lt;/p&gt;

Battaglin, Francesca; Puccini, Alberto; Ahcene-Djaballah, Selma; Lenz, Heinz‐Josef

doi:10.2147/cmar.s186042

Cited by 26 publications

(18 citation statements)

References 78 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Panitumumab, a fully human mAb against EGFR, was approved for the treatment of metastatic CRC in combination FOLFIRI and FOLFOX in the first- and second-line setting [ 78 ]. Binding of panitumumab to EGFR leads to internalization of the receptor, induction of apoptosis, inhibition of cell growth, and decrease in the production of VEGF and interleukin 8 [ 79 , 80 ].…”

Section: Monoclonal Antibodiesmentioning

confidence: 99%

Monoclonal antibodies and chimeric antigen receptor (CAR) T cells in the treatment of colorectal cancer

et al. 2021

View full text Add to dashboard Cite

Colorectal cancer (CRC) is the third most common cancer and the second leading cause of cancer deaths worldwide. Besides common therapeutic approaches, such as surgery, chemotherapy, and radiotherapy, novel therapeutic approaches, including immunotherapy, have been an advent in CRC treatment. The immunotherapy approaches try to elicit patients` immune responses against tumor cells to eradicate the tumor. Monoclonal antibodies (mAbs) and chimeric antigen receptor (CAR) T cells are two branches of cancer immunotherapy. MAbs demonstrate the great ability to completely recognize cancer cell-surface receptors and blockade proliferative or inhibitory pathways. On the other hand, T cell activation by genetically engineered CAR receptor via the TCR/CD3 and costimulatory domains can induce potent immune responses against specific tumor-associated antigens (TAAs). Both of these approaches have beneficial anti-tumor effects on CRC. Herein, we review the different mAbs against various pathways and their applications in clinical trials, the different types of CAR-T cells, various specific CAR-T cells against TAAs, and their clinical use in CRC treatment.

show abstract

Section: Monoclonal Antibodiesmentioning

confidence: 99%

Monoclonal antibodies and chimeric antigen receptor (CAR) T cells in the treatment of colorectal cancer

et al. 2021

View full text Add to dashboard Cite

show abstract

“… 18 EGFR overexpression occurs frequently in CRC, with 60–80% of tumors estimated to overexpress the receptor, 19 and overexpression is associated with a poor prognosis. Antibodies targeting EGFR (eg, cetuximab and panitumumab) are a preferred front-line treatment for mCRC, 20 provided tumor profiling for biomarkers associated with innate resistance to anti-EGFR therapy does not contraindicate their use. 21 However, biomarker screening may yield ambiguous results with tumor heterogeneity a confounding factor.…”

Section: Current Biomarker-based Stratification Of Mcrcmentioning

confidence: 99%

Recent Advances in Our Knowledge of mCRC Tumor Biology and Genetics: A Focus on Targeted Therapy Development

Gmeiner¹

2021

OTT

View full text Add to dashboard Cite

Metastatic colorectal cancer (mCRC) remains a highly lethal malignancy although considerable progress has resulted from characterizing molecular alterations such as RAS mutation status and extent of microsatellite instability (MSI) to guide optimal use of available therapies. The availability of gene expression profiling, next generation sequencing technologies, proteomics analysis and other technologies provides high resolution information on individual tumors, including metastatic lesions to better define intra-tumor and inter-tumor heterogeneity. Recent literature applying this information to further customize personalized therapies is reviewed. Current biomarker-based stratification used to select optimal therapy that is personalized to the mutation profile of individual tumors is described. Recent literature using whole exome sequencing of metastatic lesions and primary CRC tumors and other advanced technologies to more fully elucidate the tumor biology specific to mCRC sub-types and to develop more precise therapies that improve outcomes is also reviewed.

show abstract

“…Novel targeted agents including VEGF, EGFR, and, more recently, immune checkpoints and BRAF inhibitors have become available for the treatment of metastatic colorectal cancer, adding to standard chemotherapy with 5-fluorouracil, oxaliplatin, and irinotecan. 70…”

Section: Moving Away From a One-size-fits-all Approachmentioning

confidence: 99%

Redefining Colorectal Cancer by Tumor Biology

Salem

Puccini

Tie

2020

American Society of Clinical Oncology Educational Book

Self Cite

View full text Add to dashboard Cite

Colorectal cancer treatment has undergone a paradigm shift. We no longer see this disease as a singular, anatomic tumor type but rather a set of disease subgroups. Largely because of a better understanding of cancer biology and the introduction and integration of molecular biomarkers—the premise of precision therapy—we are beginning to direct treatments toward the right tumor target(s) in the right patients. The field of molecular profiling is continually evolving, and new biomarkers are constantly being discovered that have investigational, therapeutic, and/or prognostic implications—negative or positive. To date, only a few biomarkers have sufficient actionable, clinical implication to earn international guideline-recommended routine testing. Hence, it is vital that the treating oncologist should know which biomarkers to assess, when in the treatment course to test for them, and how the test is to be done. Correct interpretation of profiling results is imperative. Herein, we focus on international guideline-recommended mutation testing for patients prior to their colorectal cancer treatment initiation. The clinical applications of circulating tumor DNA (ctDNA) in patients with metastatic disease, based on our current knowledge and capabilities, are also addressed.

show abstract

<p>The impact of panitumumab treatment on survival and quality of life in patients with <em>RAS</em> wild-type metastatic colorectal cancer</p>

Cited by 26 publications

References 78 publications

Monoclonal antibodies and chimeric antigen receptor (CAR) T cells in the treatment of colorectal cancer

Monoclonal antibodies and chimeric antigen receptor (CAR) T cells in the treatment of colorectal cancer

Recent Advances in Our Knowledge of mCRC Tumor Biology and Genetics: A Focus on Targeted Therapy Development

Redefining Colorectal Cancer by Tumor Biology

Contact Info

Product

Resources

About